Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials-Reference-Cited by-同舟云学术

Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials

Published:2023-07 Issue:1 Volume:104 Page:181-188
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Heerspink Hiddo J.L.,Jongs Niels,Neuen Brendon L.,Schloemer Patrick,Vaduganathan Muthiah,Inker Lesley A.,Fletcher Robert A.,Wheeler David C.,Bakris George,Greene Tom,Chertow Glenn M.,Perkovic Vlado

Publisher

Elsevier BV

Subject

Nephrology

Reference25 articles.

1. Chronic kidney disease;Webster;Lancet,2017

2. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in Collaboration with the US Food and Drug Administration and European Medicines Agency;Levey;Am J Kidney Dis,2020

3. Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)

4. GFR decline as an endpoint for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug and Administration;Levey;Am J Kidney Dis,2014

5. International consensus definitions of clinical trial outcomes for kidney failure: 2020;Levin;Kidney Int,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope;Kidney International;2024-08

2. A new perspective on proteinuria and drug therapy for diabetic kidney disease;Frontiers in Pharmacology;2024-07-31

3. Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice;American Journal of Physiology-Cell Physiology;2024-04-01

4. Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease;Clinical Kidney Journal;2024-03-19

5. Posoleucel in Kidney Transplant Recipients with BK Viremia;Journal of the American Society of Nephrology;2024-03-12